Navigation Links
CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
Date:4/16/2012

KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is to improve the diagnosis and treatment of hemophilia in developing countries. In 2009, CSL Behring was the first company to make such a three-year commitment to WFH. CSL Limited, parent company to CSL Behring, is committed to contributing to the economic, social and environmental well-being of its communities. As part of the agreement, CSL Behring will provide 2 million units of one or more of its various clotting factor products to the WFH each year for three years.

"CSL Behring is proud to be a strong supporter of the World Federation of Hemophilia and to have been a contributor to the GAP program each year since it was established," said Paul Perreault, President of CSL Behring. "We are committed to serving people who have rare and serious bleeding disorders and we will continue to work toward solutions that make a positive impact for hemophilia patients and their communities in regions of the world where those solutions are needed most."

Blood clotting factor is manufactured from purified human plasma or by using recombinant technology.

CSL Behring clotting factor is manufactured in: the Kankakee, IL, USA facility of CSL Behring; in Melbourne, Australia, at the company's Broadmeadows facility, and in Marburg, Germany.

"The product donations we receive from CSL Behring help us to support hemophilia patients in many remote areas of the world where access to these life-saving medicines is extremely challenging," sa
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
2. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
3. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
4. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
5. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
6. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
7. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
8. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
9. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
10. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
11. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... Nov. 4 CVS Caremark (NYSE: CVS ) ... position of SVP, Marketing for its pharmacy benefit management ... marketing from Jack Bruner, who is transitioning to the ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings ...
... 4 Neuronascent, Inc., a privately-held biotechnology company ... of depression, Alzheimer,s disease, Parkinson,s and other neurodegenerative ... agreement with ChemRar Pharma, a Russian biotechnology start-up ... and stem cells to treat cancer. Under the ...
Cached Medicine Technology:Company Appoints New SVP, Marketing for PBM Business 2Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform 2
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/28/2015)... March 28, 2015 Rocket Pure , ... announced the release of their new natural sunscreen. They ... ounce packages. Both options come with a bonus lip ... RocketPure.com or on Amazon. Click to see the ... that the natural sunscreen is made with non-nano zinc oxide ...
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... 2015 highlighted a problem which could prove critical to ... Why system testing, a critical aspect of data security, ... payment card industry data security report, every major category ... vulnerability scanning and penetration testing. “With all the craziness ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients with ... presented today at the American Orthopaedic Society for Sports ... compared results for 170 patients who received rotator cuff ... capsule release procedure to relieve stiffness at the time ... from St. George Hospital in Sydney, Australia. “Both groups ...
Breaking Medicine News(10 mins):Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... the past, it was thought that one of the selective ... the development of new behaviour to respond to the ecological ... a sudden reduction in food or the appearance of a ... and researcher at the Centre of Ecological Research and Forestry ...
... Today during the 88th General Session & Exhibition ... Barcelona, Spain, S. Offenbacher will present an abstract ... of Candidiasis-Associated Denture-Stomatitis." The goal of the ... in Candida albicans (a parasitic fungus that can ...
... of Orthopaedic Surgeons (AAOS) has approved and released an ... Joint Osteoarthritis." This major joint in the shoulder ... affected by osteoarthritis, causing pain, loss of function, and ... Rolando Izquierdo, MD, chair of the Academy work group ...
... By E.J. Mundell HealthDay Reporter , THURSDAY, ... Mary Cusack has been raising her son, Nicky, she,s become ... Nicky and others with autism often display. If left unchecked, ... and her husband, Tom, have found a solution to the ...
... conducting a clinical trial that targets malignant T-cell lymphoma, a ... affects the white blood cells that normally protect against illness, ... lymphomas are of B-cell origin, and 15% of T-cell origin. ... respond well to chemotherapy. Therefore, says Arthur ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, July 14 ... the risk of heart attack more than other medications of ... controls, a U.S. government advisory panel recommended late Wednesday. ... experts rejected the option that the U.S. Food and Drug ...
Cached Medicine News:Health News:The protective brain hypothesis is confirmed 2Health News:New research finds major activation themes in denture-stomatitis 2Health News:Shoulder arthritis? What patients need to know before treatment 2Health News:Shoulder arthritis? What patients need to know before treatment 3Health News:Gentle Horses Help Rein in Autism in Kids 2Health News:Gentle Horses Help Rein in Autism in Kids 3Health News:Gentle Horses Help Rein in Autism in Kids 4Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 2Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 3Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 4
... Analyzer II is a ... to enumerate fluorescently labeled ... selected and aligned. The ... CellTracks® Analyzer II, a ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: